David Dolphin
David Dolphin | |
---|---|
Born | |
Alma mater | University of Nottingham Harvard University |
Awards | Order of Canada |
Scientific career | |
Fields | Biochemistry |
David H. Dolphin, OC FRS FRSC (born January 15, 1940) is a Canadian biochemist.
He is an internationally recognized expert in porphyrin chemistry and biochemistry. He was the lead creator of Visudyne, a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
Born in
He is Chief Executive Officer of the BC Innovation Council and Vice-President, Technology Development at Quadra Logic Technologies Incorporated (QLT Inc.).
He is a Fellow of the Royal Society of Canada, the Royal Society, Canadian Institute of Chemistry, and the Royal Society of Chemistry. In 2006, he was made an Officer of the Order of Canada.[1] In 2005, he was awarded the Gerhard Herzberg Canada Gold Medal for Science and Engineering, "with a guarantee of $1 million in research funding over the next five years from the Natural Sciences and Engineering Research Council (NSERC)".[2] In 2012, he was awarded the Queen Elizabeth II Diamond Jubilee Medal.[3]
References
- "Dr. David Dolphin". NSERC. Archived from the originalon March 18, 2005.
- "Board of Directors biography". Michael Smith Foundation for Health Research. Archived from the original on December 4, 2008.
- ^ Order of Canada citation
- ^ "NSERC - University of British Columbia Professor and Lead Creator of Key Ophthalmic Drug Wins Top Canadian Science Prize". www.nserc-crsng.gc.ca. Archived from the original on 11 December 2006. Retrieved 13 January 2022.
- ^ "Queen Elizabeth II Diamond Jubilee Medal". Archived from the original on 2012-12-04.